Volume 4, Issue 3 October 2010
To date, the only available subdermal implant used for contraception in the UK has been Implanon, which contains 68 mg etonogestrel. In October this year, a new product—called Nexplanon—replaces Implanon. Nexplanon also contains 68 mg etonogestrel and is bioequivalent to Implanon. Similar to Implanon, Nexplanon can be used for up to 3 years, and is removed in the same way as Implanon.
Nexplanon differs from Implanon in two ways:
Practitioners who currently insert Implanon should become familiar with the new Nexplanon, and should complete both theoretical and practical training before attempting to use it. An online visual training programme includes animation of the insertion technique. Once completed, model-arm training with a placebo implant is strongly recommended. Further details about the training programme and how to obtain placebo devices can be found on the manufacturer’s website: www.nexplanon.co.uk/training, or by contacting 0844 556 1444. Further details about training can also be found at the Faculty of Sexual and Reproductive Healthcare website www.ffprhc.org.uk/
Implanon will now be discontinued. However, you can continue to prescribe, dispense, or fit any remaining Implanon stock you may have.
Advice for healthcare professionals:
Nexplanon is also our highlighted Patient Information Leaflet of the month (see article O1).
Article citation: Drug Safety Update Oct 2010, vol 4 issue 3: A1.